BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 26143433)

  • 1. New World and Old World Leishmania Infections: A Practical Review.
    Kevric I; Cappel MA; Keeling JH
    Dermatol Clin; 2015 Jul; 33(3):579-93. PubMed ID: 26143433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: A Single-Center Case Series on Skin Manifestations of Leishmaniasis from a Non-Endemic State in Southern India.
    Tharakan SJ; Peter Cv D; Karthik R; Rupa V; Rose W; Thomas M; Manuel M; Rupali P; Pulimood S; Rao Ajjampur SS
    Am J Trop Med Hyg; 2020 Dec; 104(3):928-933. PubMed ID: 33377447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal leishmaniasis . Current scenario and prospects for treatment.
    Amato VS; Tuon FF; Bacha HA; Neto VA; Nicodemo AC
    Acta Trop; 2008 Jan; 105(1):1-9. PubMed ID: 17884002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology of imported cases of leishmaniasis in Australia from 2008 to 2014.
    Roberts T; Barratt J; Sandaradura I; Lee R; Harkness J; Marriott D; Ellis J; Stark D
    PLoS One; 2015; 10(3):e0119212. PubMed ID: 25734905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of using recombinant DNA species-specific probes for the identification of tropical Leishmania.
    Barker DC; Gibson LJ; Kennedy WP; Nasser AA; Williams RH
    Parasitology; 1986; 92 Suppl():S139-74. PubMed ID: 3012443
    [No Abstract]   [Full Text] [Related]  

  • 6. Leishmaniasis.
    Herwaldt BL
    Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives.
    Handler MZ; Patel PA; Kapila R; Al-Qubati Y; Schwartz RA
    J Am Acad Dermatol; 2015 Dec; 73(6):897-908; quiz 909-10. PubMed ID: 26568335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
    Kumar D; Kulshrestha A; Singh R; Salotra P
    Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
    Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
    Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Options for Visceral Leishmaniasis and HIV Coinfection.
    Monge-Maillo B; López-Vélez R
    AIDS Rev; 2016; 18(1):32-43. PubMed ID: 26936761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
    Eichner S; Thoma-Uszynski S; Herrgott I; Sebald H; Debus A; Tsianakas A; Ehrchen J; Harms G; Simon M; Sunderkötter C; Bogdan C
    Eur J Dermatol; 2013 Apr; 23(2):218-23. PubMed ID: 23557633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis.
    Crone CG; Helleberg M
    J Travel Med; 2020 Feb; 27(1):. PubMed ID: 31776570
    [No Abstract]   [Full Text] [Related]  

  • 17. Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis.
    Buonomano R; Brinkmann F; Leupin N; Boscacci R; Zimmermann A; Müller N; Fux CA
    Scand J Infect Dis; 2009; 41(10):777-81. PubMed ID: 19593691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 19. Case Report: Mucosal Leishmaniasis in New York City.
    Murray HW; Eiras DP; Kirkman LA; Chai RL; Caplivski D
    Am J Trop Med Hyg; 2020 Jun; 102(6):1319-1322. PubMed ID: 32228792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical mucocutaneous involvement with Leishmania donovani.
    Pulimood SA; Rupali P; Ajjampur SS; Thomas M; Mehrotra S; Sundar S
    Natl Med J India; 2012; 25(3):148-50. PubMed ID: 22963292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.